October 10, 2024 11:07 AM EDT
Deals
AI

AI biotechs Re­cur­sion and Ex­sci­en­tia first held deal talks in 2022

Kyle LaHucik

Senior Reporter

When Re­cur­sion Phar­ma­ceu­ti­cals and Ex­sci­en­tia an­nounced plans to merge in Au­gust, it marked the first ma­jor con­sol­i­da­tion in the

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Ex­clu­sive: How an ac­ci­den­tal email tipped Pfiz­er off to an ac­tivist in­vestor’s plan

Star­board launch­es first sal­vo in Pfiz­er fight, al­leg­ing ex-CEO, CFO were pres­sured to flip

For­mer Pfiz­er CEO and CFO flip on ac­tivist and say they now sup­port com­pa­ny

Grit­stone files for bank­rupt­cy, says it could forge a trans­ac­tion as ear­ly as this month to keep R&D go­ing

Ono’s ADC deal; Leo Phar­ma to con­duct lay­offs

Sen. War­ren urges FTC to ‘care­ful­ly scru­ti­nize’ No­vo-Catal­ent deal over com­pe­ti­tion con­cerns

A service from the Financial Times